Study! Hydroxychloroquine + Azithromycin improved survival by nearly 200% in ventilated COVID patients

But…but…Orange Man Bad!!!!

Most importantly, this is the first clinical study to demonstrate the remarkable benefit of using cumulative doses of HCQ>3g/AZM>1g, compared to those not treated with this combination.

Why did such a large effect miss observation? For one thing, HCQ produces its benefit by cumulative effects on the target cells, which is weight-dependent. The failure to treat patients with weight-adjusted doses leads to ineffective treatment and outcomes biased towards lighter patients.

HCQ is both safe and tolerable at higher doses, as shown in studies of rheumatoid arthritis or lupus. Such high doses for such long durations have not been used to treat COVID-19.

Continue reading>>>

Top Stories

    Leave a Reply

    Your email address will not be published. Required fields are marked *